Evidence map›Paper›PMID 31623428›Full record

ArticleJournal of the International AIDS Society2019

Implementation of "Treat-all" at adult HIV care and treatment sites in the Global IeDEA Consortium: results from the Site Assessment Survey.

Ellen Brazier, Fernanda Maruri, Stephany N Duda, Olga Tymejczyk, C William Wester, Geoffrey Somi, Jeremy Ross, Aimee Freeman, Morna Cornell, Armel Poda and 8 more

Abstract read
In one paragraph

Article in Journal of the International AIDS Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ellen BrazierInstitute for Implementation Science in Population Health, City University of New York, New York, NY, USA.ORCID 0000-0002-8514-1958
Fernanda MaruriDepartment of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN, USA.
Stephany N DudaDepartment of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, USA.
Olga TymejczykInstitute for Implementation Science in Population Health, City University of New York, New York, NY, USA.ORCID 0000-0002-8417-0650
C William WesterDepartment of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-8375-3926
Geoffrey SomiNational AIDS Control Programme, Dar es Salaam, Tanzania.
Jeremy RossTREAT Asia, amfAR, The Foundation for AIDS Research, Bangkok, Thailand.
Aimee FreemanBloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Morna CornellSchool of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Armel PodaHôpital de Jour, Service des Maladies Infectieuses, CHU Souro Sanou, Bobo-Dioulasso, Burkina Faso.
Beverly S MusickSchool of Medicine, Indiana University, Indianapolis, IN, USA.
Fujie ZhangClinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Keri N AlthoffBloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Catrina MugglinInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
April D KimmelSchool of Medicine, Virginia Commonwealth University, Richmond, VA, USA.ORCID 0000-0002-3966-8476
Marcel YotebiengCollege of Public Health, The Ohio State University, Columbus, OH, USA.ORCID 0000-0003-2110-2631
Denis NashInstitute for Implementation Science in Population Health, City University of New York, New York, NY, USA.ORCID 0000-0002-3280-5386
IeDEA Consortium

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
North American AIDS Cohorts on Collaboration and Design (NAACCORD)U01AI069918 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Keri Nicole Althoff, RICHARD Douglas MOORE · 2006 to 2026
$65.2M
East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional ConsortiumU01AI069911 · NIAID · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI AGGREY SEMWENDERO SEMEERE, Kara Kay Wools-Kaloustian · 2006 to 2026
$57.7M
Observational Antiretroviral Studies In Southern Africa (OASIS) CollaborationU01AI069924 · NIAID · UNIVERSITAT BERN · PI Cleophas Chimbetete, Mary-Ann Davies · 2006 to 2026
$55.9M
The Asia-Pacific HIV Research CollaborationU01AI069907 · NIAID · FOUNDATION FOR AIDS RESEARCH · PI ANNETTE H SOHN · 2006 to 2026
$44.8M
CCASAnet: Caribbean, Central and South America NetworkU01AI069923 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Pedro Enrique Cahn, Jessica L Castilho · 2006 to 2026
$41.6M
"Enhancing Cancer Research in Central Africa IeDEA"U01AI096299 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Denis Nash, Marcel Yotebieng · 2011 to 2026
$35.8M
WADA (West Africa Database on Antiretroviral Therapy) CollaborationU01AI069919 · NIAID · UNIVERSITY OF BORDEAUX II · PI Didier Koumavi Ekouevi, Antoine Jaquet · 2006 to 2026
$29.9M
NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI027763NIAID NIH HHS U01 AI069907NIAID NIH HHS U01 AI069911NIAID NIH HHS U01 AI069918NIAID NIH HHS U01 AI069919NIAID NIH HHS U01 AI069923NIAID NIH HHS U01 AI069924NIAID NIH HHS U01 AI096299
6 · The paper itself

Abstract

introductionSince 2015, the World Health Organization (WHO) has recommended that all people living with HIV (PLHIV) initiate antiretroviral treatment (ART), irrespective of CD4+ count or clinical stage. National adoption of universal treatment has accelerated since WHO's 2015 "Treat All" recommendation; however, little is known about the translation of this guidance into practice. This study aimed to assess the status of Treat All implementation across regions, countries, and levels of the health care delivery system.

methodsBetween June and December 2017, 201/221 (91%) adult HIV treatment sites that participate in the global IeDEA research consortium completed a survey on capacity and practices related to HIV care. Located in 41 countries across seven geographic regions, sites provided information on the status and timing of site-level introduction of Treat All, as well as site-level practices related to ART initiation.

resultsAlmost all sites (93%) reported that they had begun implementing Treat All, and there were no statistically significant differences in site-level Treat All introduction by health facility type, urban/rural location, sector (public/private) or country income level. The median time between national policy adoption and site-level introduction was one month. In countries where Treat All was not yet adopted in national guidelines, 69% of sites reported initiating all patients on ART, regardless of clinical criteria, and these sites had been implementing Treat All for a median period of seven months at the time of the survey. The majority of sites (77%) reported typically initiating patients on ART within 14 days of confirming diagnosis, with 60% to 62% of sites implementing Treat All in East, Southern and West Africa reporting same-day ART initiation for most patients.

conclusionsBy mid- to late-2017, the Treat All strategy was the standard of care at almost all IeDEA sites, including rural, primary-level health facilities in low-resource settings. While further assessments of site-level capacity to provide high-quality HIV care under Treat All and to support sustained viral suppression after ART initiation are needed, the widespread introduction of Treat All at the service delivery level is a critical step towards global targets for ending the HIV epidemic as a public health threat.

Indexed as

Global HealthAdultAnti-HIV AgentsCD4 Lymphocyte CountDelivery of Health CareFemaleHealth FacilitiesHIV-1HIV InfectionsHumansMaleSurveys and QuestionnairesTime FactorsWorld Health OrganizationAnti-HIV Agentsantiretroviral treatmentguideline implementationHIVHIV care“Treat all”

Identifiers

PMID31623428
PMCPMC6625339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.